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Sf.nfOl~, calif”rnio 
Tbecardiacrokaseand totaltwdyand noalcleammwmd 
the hemodynamtc, renal and endarrino eiTwts af twreasing 
dmep of ~eial n~tri”retk pp(idr were twestigsted i” 12 
padents with severe chronic congortive heart failure. Im- 
munorfactivr arterial plasma kvels of “trial natriuretic 
peptide were lO.fdd higher than nomud and ttwe IM rm 
mmtatio” btwee” wrtic atrial natriuretic pptide and 
wdtt ttlltng pressures. The tK%ut rekaxd aal natrt- 
“ret* pepttde into the cornnary sinus. The kidney, ch0q.h 
a major dcuanee de, acccmrded for ordy 334. af the total 
bady ckarance. Administration 010.3 f&g pw tin atrkd 
nabiuretic peptide p&u& signiScant ohnngs in heart 
rplr,9514,~85d4bpP”miu,andmennartcrial(9L, 
s‘onrs~a”g~,li~tabv,t3+3ms~ZnnHg) 
and mean pulmmpry artery oecladed (27 + 3 to 14 * 3 mm 
Hr) “ressures. Atrial natriuretii w”tide increased cardiac 
hii& (2.25 * 0.111 to 2.85 * 0.i itterdmin per 3) and 
stmke war* hrdex (3, 2 1.5 to r) + 3.4 ghn?, whereas 
systemic vaxular rsistara (1,424 t 139 to 1,033 f 97 
dyes.ccm-s) decreased. 
lnfusian of 0.1 p&g per min *iat nawi”red~ pepd& 
increased urinary tlw 128%. frecdmmt exaedal of IO- 
diuml338 andfmcdaalexcret&of”&sst”m35%.~ 
fdtration fraction tncrwed imm 29 2’2 to 31 + 4%. This 
reprwoted a dispmpwtiwPte ti in gkawwkr fdbsfioa 
Mammalian atrial cardiccytes contain secretorylike granules 
characteristic of endocrine tissue (I). Earlier studies (2. 3) 
have demonstrated that edracts prepared fmm rat atria 
contain factors that produce diuresis and natriuresis in viva. 
Several str”cturallv related peptides known collectively as 
atrial natriuretic ~&IS h&been isolated, purified and 
sequenced in animal (4) and human atria (5). The main 
peptide in these storage granules is the I26 amino acid, 
pro-atrial natriuretic peptide (gamma-hANP or MNP,~,& 
but the principal circulatmg form in human plasma is pmb 
ably the 28 amino acid, u-human atrial natriuretic peptide 
(alpha-hANP or hANPge,3 (5.6). The physiologic and 
pharmacologic properties of these related peptides appear to 
reside in the C-terminal amino acid sequence. In addition to 
promoting diuresir and oatriuresis, these peptides also have 
potent vasarelaxant (7.8) and endocrine e5ects such as 
inhibition of adrenocorticostemid and rain secretion (91. 
Recent studies have examined the physiologic effects of 
atrial natriuretic peptide in humans. Infusions of low doses 
of this peptide in normal subjects have indoced diuwis and 
natriuresis. After b&s infusions of atrial nawiurctic peptide, 
some investigators (IO) have reported renal hut not endo- 
crine &.cts. Others administering continuws infusions of 
doses ranging from 0.03 to 0.1 &kg per min have reported 
renal. vascular and endacrine effects (11). 
The role of atrial natriuretic peptide in heart failure is 
undetermined. Heart failure is associated wtth marked renal, 
aodocline and vascular abnormalities. Currently available 
treatments for heart failure accentuate many of these abnar- 
malities by inducing activation of the adrenergic and renin- 
angiotensin-aldosterone systems. Because atrial nalriuretic 
peptide appears to inhibit aldosterone and cortisol release in 
nomn! perxms, its nattiuretic, diuretic and vasorelaxant 
properties are potentially beneficial to patients with heart 
failure. Recently, immunoreactive levels ofthis peptide have 
been shown to he elevated in patients with heart failure 
(12.13). It is still unclear whether these elevated levels of 
immunoreactive peptide represent he 28 amino acid biolog- 
ically active alpha-human atrial natriuretic peptide. We 
recently observed (14) that coronary sinus levels of immu- 
noreactive peptide are higher than levels measured with a 
sensitive and specific biological assay. Bolus and continuous 
infusions of atrial nattiuretic peptide in patients with heart 
failure, in doses equal to those shown to be effective in 
normal subjects, have failed to produce significant diuretic 
and natriuretic effects (1 l,lS). The purpose of the present 
study was to determine the renal, hemodynamic and endo. 
crine effects of iscxasing doses of a synthetic analog of 
atrial natriuretic peptide in patients with severe chronic 
heart failure. We also measured the release of this hormone 
by the heart and its renal and total body clearance. 
Methods 
Stud) patients (Table 1). Eleven men and one woman, 
aged 33 to 51 years, with class II to IV congestive heart 
failure (New York Heart Association criteria) gave informed 
consent after the experimental protocol was approved by the 
Hospital Ethics Committee. The study group consisted of 
patients referred to Stanford University Medical Center to 
be evaluated for heart transplantation. Eight patients had 
dilated idiopathic cardiomyopathy, three had cwmary ar- 
tery disease and one had antic valve disease. Renal and 
hepatic function was adequate, as determined Ly normal 
serum cre;ltinine and hepatic transatninase nzymes. Pa- 
tients with a recent history of myocardial infarction, hyper- 
tension or urinary tract disease were excluded from the 
study. Three days before the study, all vasodilatxs, nonste- 
mid anti-inflammatory drugs, diuretic drugs ar,d adrenergic 
and calcium channel blocking a ents were discontinued (Fig. 
I). Anticoagulants and antianhythmic agents and digitalis 
were not withheld. 
The patients were admitted to the Clinical Research 
Center and given a cat&i, e-free 20 mEq sodium. 60 mEq 
potassium diet. On the morning 0fti.e 4th hospital day. the 
pulmonary and radial arteries were catheterized under Ruo- 
mscopic control and a catheter was inserted into the blad- 
der. A priming and a sustaining infusion of para- 
aminohippurate and inulin was commenced. During 
pulmonary artery catheterization, blood samples for immu- 
noreactive atrial natriuretic peptide were obtained in rapid 
sequence from the superior and inferior venae cavae, renal 
vein, coronary sinus, pulmonary artery and aorta. A periph- 
eral vein catheter was also inserted for infusion of atrial 
natriuretic peptide. 
Study daign (Fig. 1). Baseline measurements were re- 
corded in the coronary care unit after a i h equilihrati?n 
period and after obtaining stable (<IQ% varia&n) right 
atrial. pulmonary artery occluded and radial artery pres- 
sures. Urinarv Row rate and utinarv sodium, raassium. 
inulin, panr&inohippurate. creatinine and cyclieguanosine 
monophosphate (cGMP) levels were measured every 30 mitt. 
At the beginning of the baseline period. time -@I min, the 
bladder was emptied and the urine discarded. An arterial 
blood sample was drawn for hemstwrit, serum sodium, 
potassium. w&nine, inulin and paraaninobippurate. 
Urine and blood were then collected every 30 min for 
pawaminohippurate sod inulin aad hourly for kmalocril. 
creadoine and electrolyte determinations. Cadi-e outpat 
was measured by thermodilutinn intracardiac prers,rcr 
were recorded eveq 30 min. and cardiac otitpot was me”. 
sued in triplicate every 60 min. 
Heginning at time 0 +I20 and +!40 min. the patie”:% 
receii,cd I h inhsmos of alpha-homan at, i”I niltriorelic 
peotideizX (alpha-hANP,_:,: Anaratide. Wyeth Laborato- 
tier). This “gent is a 25 amino a:id peptide that has similar 
biologic activity and the same amino acid sequence as the 28 
amino acid alpha-human “trial nalriuretic prptidc. except 
that alpha-human alrial natriurctic peptide,,, lacks three 
amino acids from the amino temtiw. A I h recovery period 
followed each I h infusion; hence. there YCW ow baseline 
and three infusion and recovery pcriodb. To ide”!ify a safe 
and effective dosage. the patients were sequentially “ssigoed 
to a low (0.03,0.06.0.1 #dkg per min). medium@. I. 0.2.0.3 
lrdkg pr min) or high (0.3,0.45,0.6 &kg per min, infusion 
regimen. Three patients received 0.03.0.06 and 0.1 &kg per 
min. seven patients received 0.1.0.2 and 0.3 !&kg per min 
and two received 0.3.0.45 and 0.6 &kg per min. Before the 
txxt increment”1 dose. blood was drawn for “trial natriuretic 
peptidc determinations. The volume of urine excreted over 
the prior hour was replaced intravenoosly during the subre- 
qttent hour with 5% dextrose in 0.2% saline solution. At the 
end of toe third recovery period. all catheters were removed 
and the patients transferred to the !tospital’s Ctinical Re- 
search Center. 
holocol for plasm” renln activity, aldasterone ““d nowpi- 
nephrlne determinali”~. On the followmg 2 days, the pa- 
tients received B 2 h infusion of atrial nalriuretic pqtide on 
! d”y and a similar volume of IO0 m&al mannitcl in O.d95 N 
acetic acid as dilucnt placebo on the other day. The se 
quence of placebo and atrial natriurcdc peptide was reversed 
in every other patient. The potpare of this protxol WE to 
stcdy the etfefe-ts of “trial natriuretic peptide on :he levels of 
plasma rentin actiwty. aldosterone and norepinephrioe and to 
determine the volume of dtstribution and total body clear- 
ante of the hormone. The studies were done in the mornig. 
The first morning void started ” 2 h baseline ariod. during 
which the patients attempted to void every 30 min. Before 
the end of the baseline period. with the p”tae”t in the cupine 
padion for 130 min. blood somplcs from an internal jugulnr 
catheter were drawn for hematocrit. plasma aldostemne. 
reltin activity. “trial natrioretic peptide and norepinephiine. 
Bloal was “ISO collected for swum sodium, potassium. 
chloride. crcarimns a:td osmoltdity. Aeart rate and CUR 
blood pressure were record& exry 5 min. Three Qatienls 
rccewed a ? h infusion “f 0.1 &kg per min. and sewn 
received B” infudon of 0.3 &kg per min of the pepiide. 
Renzl and bcmcdynamic data were not anaiyred in two of 
these seven paticnts because of either symptomatic hypo- 
tension or ‘iiolations of the protc;ol. One patient received an 
mfurm of 0.6 &kg pzr min. R:ients were asked to urinate 
every 30 min. Blond was collected for immunoreoctive 
peptide at 30 min and at the end of the infusion. and also at 
5 and 15 min into recovery. Blaod for bcmatocrit. serum 
osmolality. crearinine. so&m. potassium and chloride de- 
terminations was drawt at 60 min and at the end of the 2 h 
infusion and recovery periods. At the end of the 2 h recovery 
period. any urine voided during the experimental and recov- 
cry peiiods in ercess of that predicted by the baselioe rate 
‘.a\ replaced by iatrwenous infusion of JI dcxtrosr in 0.2% 
saline sohmon over 3 h. 
Nine patients completed and talented all phases of the 
protocol. One patient was removed from the study after the 
hrmodyran!ic protocol because of anemia. Another patrent 
was withdrawn because of unstable angina before the ? h 
inforion of atrial natriuretic peptide. and a third was with- 
dr;lwn because of symptomatic hypatension during infusion 
of 0.45 @g/kg per min. 
Analytic detennioatiim. Mean pressures were calculated 
by electronic integration IHewlett-Packard). Themwdilution 
cardiac output. cardiac index. systemic vascular resietencz 
and stroke volume index were calculated according to stao- 
dard “nalvoc tcchniwes (16). Stroke work index (elm’) was 
calculated as aroke~volume isdex.(MAP - POP).?l.O136. in 
which MAP denotes mea” astcrial pressure and POP denotes 
mesn pulmonsr) artery occluded preseoie. 
The urinary ~olwnes were measured using graduated 
cylinders. Serum and urinary sodium, potassium, chloride 
tmilliequivaknts per liter) and creatinine (millipnns per 
decilitert concentrations were determined by standard ana- 
lytic tcchtnqurs. Serum and urinaryo~molality(milliormoles 
per kilogram) were measured by freezing point depression 
Serum and urinary inulio and para-aminohippurate were 
assayed by spectrophotometry as previously described (17). 
The renal extraction ofpara-aminohippurate was assumed to 
be SS% (18). Renal blood Row was calculated by dividing 
para-aminohippurate clearance by l.hematocrit. Fractional 
excretion was calculated as the clearance oftbe substance in 
question divtded by the glomerular filtration rate. Lhinary 
cyclic GMP was measured bv radioimmunoassay (19). 
PRsma renin activity was measu~d as the rate of im~unoas- 
sayable angiotensin 1 generated in plasma incubated at pH 
7.4 at 37°C (20). Plasma aldosterone was determined by 
radioimmunoassay as previously described (20). 
AtMI norriurcric pep.& was measwed by mdioimma- 
noassay. Blood was cohccted into chilled tubes containing 
ethyleneoiaminetetraacetic acid (4.5 mg) and aprotinin (IOtl 
KIUlml) and then centrifuged immediately at 4’C. Three 
milliliters of plasma were passed through a Sep.Wk C,, 
caRridge and strial nairiuretic pptide ‘was elnted with 70% 
acetonitrile in 0.1% trifluoroacetic acid. Mean recovery (70 2 
2%) was calcutated by adding ‘zt-atrial natriuretic peptide to 
the sample and known amounts of synthetic atrial natrluretic 
peptide to pooled human plasma. After evaporation, the 
saroples were resuspended inphosphate-buffered solution and 
assayed in duplicate. Synthetic human atrial natrluretic pep- 
tide ;Peninsnla Laboratories) was used to prepnre stdndards 
in plasma and buffer. ‘zsI-atrial natriuretic peptide was ob- 
tained tmrn Amersham. lmmnnoreactive atrial natrbtretic 
peptide was measwed with rabbit C-terminal specific anti- 
alpha-human atrlal natriuretic peptide serum obtained from 
Peninsula Laboratories. This antibody exhibited IW% cross 
reactivity with alpha-human atria; t~.ariuretic peptide,,, and 
40% to gamma-human atrial natriure:ic peptide,.,,. A IW pl 
aliquot of antiserum was incubated with 103 r.d of standard or 
sample for 24 h, and the labeled atrial natriuretic peptide was 
then added for an additional I6 to 20 h aad incubated at 4°C. 
Free and bound fractions were separated by precipitation 
with goat anti-rabbit immunoglobulin serutn after a 2 h 
incubation at room temperature. The sensitivity of this assay 
was I.2 fm/tube. Total binding was 35%, and the 58% dis- 
placement point on a standard curve was 17 pM. tntemssay 
and intmassay variability was <IO%. 
Torol hod)’ cleurancc WOE calcrdated (IS the product of 
volume of distrihudon and elitninafion role consram. The 
elimination rate constant was calculated as the slope of the 
natural logarithm of the plasma concentration versus time. 
and is equal to 0.693lelitnination plasma half-life. Volume of 
distribution was calculated by dividing the continuous intra- 
venous dose divided by the steady plasma concentration of 
the peptide and the elimmation rate constant. The elimina- 
tion half-life was calculated by dividing tlie natural ogarithm 
of 2 by the elimination tote coostwt. Tztere was no aopre- 
ciable absorption of atria1 natriuretic peptiae by the inf&on 
tubing. Plasma and infusate atrial r-ntduretic peptide were 
measured by redioimmtntoassay. 
Statisti~l anatysis, Multirde regression analysis and anal- 
ysis of variance~for epeated t&asures, with subseqtient 
Fisher and Dtmnett I tests, were used to de’crmine the 
significance of the changes observed. Paired and unpaired r 
tests were used to determine the signiticancn of single 
comparisons. All values are expressed as meat + SEM. 
Changes were considered significant at p 5 3.05. 
Baseline cardiac tilling pressures in the I2 patients were 
elevated. Mean tight atrial pressure was 1 I * 2 and mean 
pulmonary artery wcluded pressure was 26 f 3 nnn Hg. 
Despite normal serum creatinine. the glomernlar filtration 
mtebf 66 * 6 ml/min per 1.73 mz and renal blood flow of412 
t 36 mllmin mr 1.73 m’ were reduced to 50% of nomtal 
values (18). 
Plasma atria! natrinaatic paptide mneenbattnns (Fig. 2). 
Plasma levels of atrial nattiuretic peptide were detemdned 
fmm the superior and inferior venae cavae, pulmonary 
artery, renal vein and aorta in 8 of the I.2 pathart!;. The 
coronary sinus was sampled in only seven patients. The 
mean aortic plasma immunoreactive level of 242 + 48 pM 
was significantly hiaber than the reported concentration in 
normal individ&(tl) (Fig. 2a). -Amtic and puhnonary 
artery natrinretic peptide concentrations were signiticantly 
higher than those in the renal vein and inferior vena caya. 
The concentration was highest in the coronary sinus. The 
kidney extracted 82 ? 2% of the renal artery atrial natriuretic 
peptide, and the estimated renal clearance was 189 t 29 ml/ 
min per 1.73 nt’. In this group of very sick patients, there 
was no correlation between arterial atrlal nattiuretic peptide 
concentration and right atria.1 or pulmonary artery occluded 
pressures (Fig. 2B and 20 
Hemndynamic elf&s of atrial nalriuretic paptide (Fig. 3). 
Three patients received 0.03,0.06 and 0.1 &kg per min of 
strial natriuretic peptide for I h. Seven patients had an 
infusion of 0.1. 0.2 and 0.3 Irg/kg per min. By repeated 
analysis of variance and multiple regression analysis, the 
administration of atrial natriuretic peptide led to significant 
changes in heart rate (r = 0.88, p < O.OOO+, right atria! 
pressure (r = 0.95, p 5 O.wOI), pulmonary artery occluded 
pressure b = 0.91. p s O.oM)1), cardiac index (r = 0.84, p. a 
0.0801) and systemic vascular resistance tr = 0.78, p 5 
O.OMB). When baseline values are compared with maximal 
response, heart rate decreased from 95 ? 4 to 85 f 4 beats/ 
min (p 5 0.05). mean arterial pressure from 92 ? 8 to 77 * 
9 mot Hg (p L 0.05). right atrial pressure from 13 + 3 to 8 f 
Cp 5 0.0X whereas systemic vascular esistance decreased 
from 1.414 ? 139 to 1,033 + 97 dynes.s.cm-5 (p i 0.05). 
Stroke work index increased fmm 21 -C 1.5 to 29 z 3.4 g/m’ 
(p 5 0.05). Hemodynamic values tended to rehwn to baseline 
during recovery. Atnal natriuretic pptide lowered heart rate 
and pu!monary artery occluded and right atrial pressures in 
a reversible manner. In contrast, blood pressure progrcs- 
sively decreased and did not return to preitision values 
during the I h recovery periods. However, the small but 
significant decrease in blood pressure during the 2 h infusion 
of 0.1 and 0.3 &gikg per min atrial natriuretic pcptide had 
returned to preinfusion values by the end of the 2nd h of the 
recovery period (Table 2). 
Renal rqases to atried nabiuretic peptide (Fig. 4). Ten 
patients received 0.1 p&g per min of atrial narriuretic 
peptide. Three of these patients received the infusion after 
the administration of 0.03 and 0.06 &kg per tin of the 
homnme. Before the initiation of each hi&r dose, the 
plasma atrial natriuretic peptide concent~tion had returned 
to baseline values. There were no consistent renal changesat 
the 0.03 atld 0.W w’kaika per min doses. The other seven 
patients rcccived 0.1 wk,ks per min at the beginning of the 
study. The data for the 0.1 @kg per min dose in the two 
groups were comb:wd because there were no measurable 
renal effects at tb 0.03 and 0.06 doses or any diEerence in 
the renal response ofthe two groups at the 0.1 &per min 
dose. Baseline renal function was markedly abnomml, con- 
sistent with severe heart failure. The administraticm of atrial 
natriurctic pcplidc led to signScant changes in urinary flow 
rate and fractional excretion of sodium (SeeNa) and patas- 
sium (FeK). In comparison with baseline values, urinary 
flow rate increased by 128% from 1.22 ? 0.25 to 2.79 z 0.8 
ml/min (p 5 0.05). FeNa by 133% from 0.22 + 0.11 too.52 f 
0.16% (p 5 0.05) and FeK by 35% fmm 18.9 f 2.4 to 25.6 t 
4.8% (p B 0.0s). 
During drug administration the glomerular filtration rate 
increased From 68 + 6 to El + 6 mllmin per 1.73 m2 CL) 5 
Fire 1. Plasma levels ofatdal natriuretic peptide IANPI (A) and 0. IO). whereas the renal blood flow incrc&d from 363 & 19 
the r&Lion between right atrial 1R) rml pulmonary anery uccluded to 440 * 44 during the East 30 min and 395 ? 46 m!Jmin per 
(C)pressures with arterial &ma concentr~rions. Blomi for immu- 
noreactive atria! nawiuredc peptide lmean +_ SEW from the rcnsl 
1.73 m’ during the second 30 min period of infusion. These 
vein (RVI, inferior WC) and superior WC) venae cwae. pulmo- 
changes in ran! blowI Row were not statistically significant: 
nary anery (Pa). aorIa lAol and coronary sinuq 0) was obtained m however, the small increase in SItration fraction indicates a 
rapid qvence in sewn paienrs. The relation between cardiac dispmporliooate levation in glomerular filtration relative to 
filling pressures and arterial plasma conccntmdons (A0 ANP) wils renal plasma flow. The increment in filtration fraction was 
determined in I2 patients. ‘Denotes ignidcnnt (p6 D.05) stepdown not associated with an elevation in renal vascular esistance. 
betweenaonic and renal vein and inferiorvena cwa conccntmdons: 
+ denotes ~gniiicantly (p a 0.05) higher than wperior and inferior 
In association with these hcmcdynamic and excretory 
venae cavae. pulmonary anery and sonic levels. 
changes. the urinary excretion of cyclic GMP increased by 
106% from I.027 * 315 to 2,091 * 612 pmoUmin. The renal 
excretion of cyclic GMP peaked during the first 30 tin of 
ICCOYWY. 
Table 2 shows rhe hemoajwomic and nmd &as of 2 h 
2 mm Hg (p S 0.05) and pulmonary artery occluded pressure infusions of mial narriureric peptide and placebo in five 
from 27 + 3 to 14 ? 3 mm Hg (p I 0.05). Cardiac index porienrs. The administration of 0.3 &kg per min of atrial 
increased from 2.25 + 0.18 to 2.83 + 0.3 lilerslmin per ma nariuretic peptide led to a small and reversible decrease in 
heart rate and mean arterial pressure. Similar to changes 
noted with I h infusions of atria1 natriuretic peptide, there 
was a significant increment in urinary Row rate. urinary 
sodium excretion and fractional excretion of sodium. There 
was also an increase in urinary potassium excretion and its 
fractional excretion. Urinary osmolality dropped from 825 2 
92 to 573 + 128 mOsmol/kg (p c 0.05). The baseline 
glomerular filtration rate in these five patients, as estimated 
by the creatinine clearance, was similar to the inulin clear- 
ances determined during the multiple dose protocol. Creat- 
inine clearance during the infusion of 0.3 &kg per min of 
atrial natriuretic peptide rncreased from 69 i IO to I02 t 28 
mUmin, hut this difference was not statistically significant. 
The infusion 010.1 @kg per min of atrial natriureti~ peptide 
led to parallel changes in renal function; however, given the 
small number of patients, these changes were not slatisti- 
tally significant. Placebo had no efiect on any of the varie- 
bles studied. 
Endocrhx effeffs and phamttiitelics of atrial ostri- 
wetic peplide. Table 2 presents the endocrine changes ob 
served during the 2 h infusions of various doses of atrial 
natriuretic p&tide. As expected in severe heart failure, 
baseline plasma atrial nattiuretic peptide, aldosterone, nor- 
epinephrine and plasma rain activity were markedly ele- 
Table 2. Hemodynamic. Renal and Endcaine EBectr of 2 Hour Infusions of Placebo and Atrial Natriuietic Peptide 
HR ,be;lW MAP U,Y PRA Wml 
Ccmd,,i0” ir*tw ,pM min, @nmitIg) “4 ,#“lnl”~ ,pE#Ini”) FeNs ,I, per h) PA (“gidl, 
3.5 f 4.‘) 0.76 -t 0 36 M t II 
wted. The 39.fold increment in plasma atrial natriuretic 
peptide at the end of the 2 h infusion was associated with a 
marked inhibition of plasma aldosterone and norepinephrine 
concentrations without a significant effect on plasma rain 
activity. All the doses of atrial natriurelic wlide had similar 
end”& effects. Plasma aldontemne d&eased 52% from 
115 + 39 to 55 + 20 ng/lOO ml (p S O.OS). LIespite the small 
decrease in arterial blocd pressure, plasma “orepinephrine 
declined from 902 zt IS2 to 667 + 114 @liter (p c 0.0s) 
without the expected increase in plasma renin activity. 
Figure 5 illusrrares rhe eliminarion half-life ofexoa@nou~ 
“trial nalriwetic peptide. The plasma half-life was 4.3 5 0.4 
min. The calculated total body clearance of the peptide was 
810 + I33 mllmin. The elimination rate constant at these 
doses indicates that clearance of atrial natriuretic peptide 
probably follows zero order kinetics. The volume of distri- 
butionofthepeptid~was5,IS5CI,l&lmlor6~I%oftotal 
body weight. 
Cardttrwat &cts of atrial oatriur& peptide. In this 
study. we investigated the phamwadynamic and phamm. 
cokinetic properties of atrial natriwetic peptide in conger 
tive heart failure. Infusion of synthetic atrial natriuretic 
Wplide in patients with heart failure produced bcneticial 
he&dynamic effects. These included arterial and ven”w 
vascular relaxation, with a concomitant decrease in pulnw- 
nary artery occluded and right atrial pressures and increased 
cardiac output and stroke work index. There was doubling of 
tension and stretch that are the important detemktants. 
Furthermore, as heart failure progresses, the volume homeo- 
Arts&i and vermus vssodilatton. Atrial natriuretic pep 
static mechanisms are reset and vasoconstriction and fluid 
accumulation occur as if there were severe volume depletion 
tide relaxes precontracted arterial muscle strips in vitro, a 
(26.27). The role of atrial nattiuretic hormone in this adsp 
tation is not clear, but because infusion of atrial natriuretic 
peptide improved the hemodynamic. renal and endocrind 
deranpments of hean failure, our data suggest hat attial 
secretion, and thereby arterial levels, may not be maintained 
at levels necessary to prevent fluid accumulation and vast- 
constriction. This may be a primary atrial process such as 
would be expected from atrial cardiocyte secretory abnor- 
malities or atrial cell loss, or both, due to atria1 fibrosis and 
calicification as seen in chronic dilated heart failure (Bil- 
liugham M, personal communication). Alternatively, atrial 
secretion may be inhibited by neurohumoral mechanisms 
activated in heart failure. Furthermore, the elevated level of 
immunoreacative atrial natriuretic peptide in heart disease 
may not completely cotrespond to biologically active pep- 
tide. 
figure 5. Plasmaelimination half-life ofexogenousatrial natriuretic 
peptide in nine patients. Blood was drwn for immunoreactive atrial 
natrturaic peptide (tn [ANPI) immcdistely, before. at 30 min and at 
1 h into the h&ion. After the infusion was discoutinued Itime 0). 
levels were obtained at 5 and at I5 min. 
urinnry Row rate, associated with natriuresis, and a slight 
pressure and increased nattiures~s, plasma aldosterone and 
increase in filtration fraction. Despite the decrease in arterial 
noreoinwhrine levels declined. but ulasma rain activity 
re&ined unchanged. Atrial natriureti~ peptide was released pnress med&ed by cyclic GMP (7.8). Furthermore. infu- 
into the ccmmary sinus and cleared by the ueriuherrd tissues. sions of peptide into bruchial artery in humans have in- 
The kidney wasa major clearance site, extracting 82% of the 
If it is assumedthat renal clearance was relatively s&bi, tb 
arterial atrial natriuretic peptide. Renal clearauce of endog- 
kidney accounted for 33% of the total elimination of this 
euous atrial natriur&ic peptide was detertuinej. I or 2 days 
before the e~ogawus clearaucc of atrial natriuretic peptide. 
creased forearm blood flow threefold by t-ela.xing resistance 
cardiac output. The hypotensi;e etTects of there peptides 
vessels (28). Infusions of atriel natriuretic peptide into 
have been attributed to a decrease in cardiac index second- 
healthy ~~hmtecr~ (II) and animals (29,30) have lowered 
cardiac filling and arterial blood pressures without increasing 
hormone. The strikingly elevated arterial levels of &al sty to diuresis and venodilation (29). However, our data 
natriuretic peptide are probably due to enhanced production indicate that atrial natriurctic peptide reduced pulmonary 
because the 4 min elimination half-life of the hormone in artery occluded and tight atrial pressure by increasing car- 
patients with heart failure does not appear to be prolonged disc output and decreasing arterial and venous resistance. 
when compared with values in healthy individuals (22). 
Atrial natriuretic peptide is also elevated in renal failure (23). 
Because the extrarenal tissues account for the principal 
disposal of this peptide (67%), the elevated immunoreactive 
lev&s present in chronic renal failure cannot be entirely 
explained by the decrease in renal clearance. Perhaps the 
elevated levels measured in renal failure represent, as in 
heart failure, enhanced release or impaired removal by 
extrarensl tissues, or both. 
Pltwna levels in heart failure. At&d natriuretic peptide is 
believed to play an important role in volume homeostasis; 
Therefore, the different hemcdynamic etfects of atrial natri- 
uretic txptide observed in healthy subjects and patients with 
heart Failure probably depend on the preresxisting level of 
vascular tone. 
In the present study, cardiac output increased and mean 
arterial blood prcsaure decreased, suggesting that atrial 
natriuretic peptide decreases peripheral resistance by exert- 
ing a direct vasorelaxant effect on the arterial circulation. 
The increase in cardiac output was due to an enhanced 
stmke work index, probably secondary to decreased imped- 
ance to flow and a decrease in heart rate. Alternatively, 
thercfore, it has been assumed that atriat pressure is au because we did nut measure left ventricular volume, we h&e 
important determinant of atrial natriuretic peptide release. not excluded an e&et of this peptide on left ventricular 
Some investigators (12,24) have shown a linear correlation diastolic compliance or a direct inotmpic effect. Further- 
between venous atrial natriuretic peptide and pulmonary more, the increased cardiac output could be solely second- 
artery occluded and tight atria1 pressures. We did not ary to a nwre favorable position in the Starling curve as a 
observe this relation. However, we compared cardiac filling result ofdecreased venous return. This possibility is unlikely 
pressures with arterial levels in this group of sick patients. because infusion of atria1 natriuretic peptide was associated 
Others (21) have also reported this lack of correlation. with a small decrease in arterial pwsure. 
Perhaps it is not intraatrial pressure, but rather atrial wsll k heart failure. otrial narriwelic p&de is apparently a 
balanced vasodilafor. Unlike atrial natriuretic peptide. ve- 
nous vasodilmors such as nmoglycenn and isosorbide dini- 
trote lower fitting pressures by primarily reducing venous 
return and not by increasing cardiac output (311. Pure 
arterial vasodilators, such as nifedipine (32) and hydralazine 
(31). rarely iower cardiac filling pressures because the in- 
creased forward flow is compensated by enbaoced venous 
retom. Atrial oatriuretic peptide relaxed the venoos and 
weriot circulation. lowered heart rote and cardiac fitting 
prewures and elevated cardiac index in a reversible manner. 
However, there was a progressive decrease in mean arterial 
blood pressure due to a slightly more prolonged effect on the 
systemic vascular resistance. The sustained arterial relaxant 
etTects of atrial natriuretic peptide in humans have also been 
described by Bolli (28) and Crazier (IS) and their coworkers. 
Blunted renal respoose. Cootiooous or bolos infusions of 
atrial natriuretic oeotide in normal subiects have oroducrd 
significant renal &&my changes (IO:1 1.33). R&d stud- 
ies (11.15) involving small groups of patients with heart 
failure receiving either bolus or continuous infusions of low 
doses have failed to show any renal effects. In Ibis study. we 
observed o doubting of urinary Row and sodium excretion. 
The reason for this discrepancy is not immediately obvious. 
Our patients were severely ill heart transplant candidates. 
Because congestive heart failure is a hetemgenous syn- 
drome, we spwtlate that the diierence in the renal rc- 
sponses among studies could be attributable to interpatient 
variability in the dit&ent patient populations. Furthermore, 
the hemcdynamic, renal and endcaine effects of diuretics or 
vasodilaton in heart failure are not always beneficial be- 
eaose the baseline status of the patient is of importance in 
the phamtacodynamic effects of cardiac drugs. Altema- 
lively, this diffetettce could have been doe to differences in 
bioavailability of the peptide. 
Fire 6. Relation between prceot change from baseline in renal 
vascular r&tame WRI nnd percent change in urinary Aow rate 
WV) and urinary sodium excretion UNa~io tbeninepatieotrwho 
received 0.1 &kg per odn atrial natriuretic peptide and who had 
rem, hemodynamic me~sureme”ls. 
It is unclear whether the renal efects ofulrial nuvinrrric 
pepride observed in healthy animals and humans we due lo 
direct rubnlar effects or represent chongm in glornerrrlor 
.filtration rate. Maack et al. (30) reported in dogs so increase 
in elomemlar filtration rate in reswnse to atrial natriuretic 
peptide, but others have not fo;nd an e&t in healthy 
subiects or oatients with heat failure (10.11.15.33). In our _ . 
study, the increases in orioary flow rate and sodium excre- 
tion elicited bv both 0.1 and 0.3 wlkfz oer min atrial 
natriuretic pepiide were associated~&h &I increase in 
filtration fraction. This was the result of a tendency for 
glometular filtration to increase more than rooal plasma flow. 
Interestingly, the small increose in filtration fraction was not 
associated with an increase in renal vascular resistance. 
There was oo inverse correlation between urinary flow and 
sodium with renal vascular resistance (Fig. 6). This tendency 
toward lower renal vascular resistance suggests that atrial 
natriuretic peptide preferentially relwd the offwent oite- 
rioles, an e&t qualitatively different from that produced by 
infusion of norepinephrine and angiotensin II, which in- 
crease filtration fraction by preferentially cootractmg the 
e&rent arterioles (34). In this respect, the renal hemody- 
namic effects of atrial natriuFetic peptide appear to be 
unique. 
Alternatively, we may speculate that the filtration tiac- 
tion increased secondary to a change in the glomerolar 
ultr&ltration coefticient (product of basement membrane 
permeability and glomerolar filtration area). In our study. 
plasma oncotic pressure or hematocrit did not change (data 
not shown). hot Cody II 1) and Maack (30) and their cowork- 
ers noted that atrial natriuretic pqtide in healthy subjects 
resulted in increased plasma oncotic pressure and hcmocon- 
centration that were not of proportion to the dioresis ob- 
served. Furthermore, it has been reported (35) that atrial 
natriuretic peptide affects the permeability and hydraulic 
orooerties of caoillwies. This peptide may a&t the trans- 
~ap&ry efRux of endovascola; i&id, either by affecting the 
capillary permeability propcnies or by increasing the intro- 
capillary hydmrtatis pressure. or bath. Atrial natriuretic 
peptide is 1 very patent stimulator of cyclic OMP in cultured 
vascukw endothelial cells (36.37). The phy.siologic signifi- on plasma renin activity in heart failure remain to be 
cance of cyclic FMP stimulation in endo~elial ceils is not determined. 
known. but we spxulate that it may be responsibio for Cyclic GMP has been proposed 11s the in~~~~~il~l‘,, 
changes in tSe permeability properties of capillaries. mrdintor of home otrial norrieretic pepride nctions 
Endcuine eRch. The vasodilatiug and renal effects of f7.38,45,46). Atrial natriuretic peptide stimulates cyclic 
atrial natriuretic peptide were associated with significant GMP in a dose.dcpcndent manner in the adrenal gland (47) 
endocrine changes. Plasma aidustemne and norepinephrhta and glomerulus and renal collecting ducts (45.48.49). Fur. 
decreased substantially whereas plasma renin activity r-s thermore, cyclic GMP accumulation and cyclic GYP 
mained unchanaed. These endocrine effects mav he either dependent protein kinase activation tn atriai natriuretic 
primary or secondary to the hemudy~mic improvement. 
The decrease in plasma norcpineph~ne could be secondary 
to the increased cardiac index and decreased filling prw 
sures. Alternatively, atrial natriuretic peptide may h&e a 
direct sympatholytic effect that contributed to the decline in 
systemic vascul& resistance (38). Our data cannot answer 
this question, but similar hemodynamic hanges induced by 
sodium nitroprusside in bcart failure have nut lowered 
plasma no~pincpb~n~ leveiv l32,39). 
PIusmt< ~id~s~eron@ kv& wre decreased .C% by atriai 
~~imeticpepepridr. The inhibition of plasma aldostcroue wu 
probably due to a direct inhibitory effect on the adrenal 
gland. Infusions into humans (II) and animals (30) and 
studies with is&t-d adrenal glands and zoua glomerulasa 
celll (9,40AIl have shown a potent inhibitory effect on 
aldoslet~x and cortisd secretion. After the 2 h infusion of 
atrial natriuretic peptide, plasma ldostemne cone~ntrationa 
decreased from I IS + 39 to 55 i 20 n&O0 ml. a concentra- 
tion that is still much areatar than normal. The physiologic 
relevnnce of this observation is unknown. However, this 
brief reduction in plasma aldosterone is unlikely to be 
responsible for the obser\ed renal changes because the 
cellular munifestations cf sldosttrune. being continaent on 
protein synthesis, require a greater time of onset. 
Atritz! ~~ufri~~refic peptide iowwd pias~a uld~~~ero~e 
c”~i~e~~lrafians bidi hnd tw @cc/ otr plasma wnh activity. 
Most diuretics and vwodiiators wdl stimulate the ranin- 
angintensin system. The abrencc of change in plasma rain 
activity despite the decrease in blaod pressure and increased 
sodium excretion suggests that lhe peptide was exerting an 
inhibitory e&t on the juxtaglomerular apparatus. The et&t 
of atrial natriuretic peptide on plasma renin activity is 
controversial. Several investigators have repted dccreascs 
in plasma rain activity in humans (ttt and in animals 130) 
whereas others have not (10,33,423. Atlas et al. (43) rug- 
gested that he effects of atrial natriuretic peptide on mnin 
release are secondary to renal hemadynamic changer. How- 
ever, the peptide has been shnwn tn directly inhibit plasma 
renin activity release from rat renal cnrtex (44). Many of our 
patients were receiving angintensin-converting enzyme in- 
hibitors and diuretics up to 3 days before the study. These 
dnas are potent stimulators of r&n release and they may 
have long-acting &ects on basai renin production. There- 
fore, the mechanisms nfsctiou of atrial natriuretic peptide 
peptide precede vascular relaxation (7.8). In this study. 
urinary cyclic GMP. urinary ilow and ranal sodium excretion 
doubled. However, these renal effecls, though similar in 
relative magnitude (twofold change), were in absolute terms 
significantly less than those produced in healthy individuals. 
Despite high circulating levels of endagenous atrial natri- 
uretic uentide. basal renal excretion of cvclic GMP was not 
different hm that observed in healthy euvolemic supine 
individuals (50). Furthermore. dmina it&&m. the levels of 
atrial natri&ic peptide were 30 to 40 times higher than 
baseline valuesand 5.W times higher than values measured 
in health!, ,water-immersed humans (51). However, this 
marked elevatm~i in this peptide was only associated with a 
small natriuresir and increase in cyclic GMP excretion to 
levels that were lower than those observed in diuresing 
hypcrvolemic water-immersed healthy subjects. This obser- 
v&n suggests that the attenuated renal responx to atrial 
natriuretic peptide observed in heart failure may be second- 
ary to atrial natriuratic peptide receptor abnormalities. 
These may include down-regulation of the guanylate cy- 
clawcoupled atrial riatriuretic peptide receptor or abnor- 
malities in guanylate cyclase activation after receptor bind- 
ing. Alternatively, other neuroendocrino abnormalities may 
have inhibited atrinl nauiuretic peptide-induced natriuresis 
and diuresis by attenuating the activation of guanylate cy- 
clase (52). 
Cuudusions. lnfusiun of several dwv of atrial natriuretic 
peptide was associated with salutary hemadynamic. renal 
and endocrine effects. Atrial natriurelic peptide produced 
significant arterial and vennus vasodilation and improved 
cardiac perfomumce in association with a mild natriuresis 
and inhibition of plasma aldosterone and norepinephrine 
levels. These effects appear to be unique. The hemndynandc 
properties of atrial natriuretic peptide arc very similar to 
those of sodium nitmprusside. exceut that atrial natriuretic 
peptide inhibits the &rcendocrind compensatory mecha- 
nisms that characterize vasodilalor therapy. Most vawdila- 
tow stimulate sodium and fluid retention by decreasing 
glomwlar filtration and activuting the renin-angiotensin. 
aldosterone system. The rennl and hemodynamic properties 
of atria1 natriuntic peptide are singular in that they have no 
effect on sodium balance or they pmduce a mud&e diu- 
resis and natriureris. This twofdd improvement in remit 
exwetnry function fell short of being the major diuresis and 
natriuresis required of therapeutic diuretic agents. However, 
the lack of &nub&n of the renin-aneiotensin-aldosterone 
system and secondary vasoconstriction. as seen with con- 
ventional diuretics (53). makes the further investigation of 
diuretic properties of&al natriuretic peptide in heart failure 
enticing. Futfhemwre, the attenuated renal excretory and 
cyclic GMP Sects of atrial natriuretic peptide in heart 
failure nay bt explained by abnormalities in the particulate 
guanylate cyclase-atrial natriurettc prptide-receptor system. 
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